- Home
- THCH vs ZURA Comparison
THCH vs ZURA Comparison
Compare THCH & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- ZURA
- Stock Information
- Founded
- THCH 2018
- ZURA 2022
- Country
- THCH China
- ZURA United States
- Employees
- THCH N/A
- ZURA N/A
- Industry
- THCH Blank Checks
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THCH Finance
- ZURA Health Care
- Exchange
- THCH Nasdaq
- ZURA Nasdaq
- Market Cap
- THCH 84.8M
- ZURA 69.9M
- IPO Year
- THCH N/A
- ZURA N/A
- Fundamental
- Price
- THCH $2.49
- ZURA $2.17
- Analyst Decision
- THCH
- ZURA Buy
- Analyst Count
- THCH 0
- ZURA 10
- Target Price
- THCH N/A
- ZURA $12.67
- AVG Volume (30 Days)
- THCH 22.0K
- ZURA 360.0K
- Earning Date
- THCH 08-26-2025
- ZURA 11-06-2025
- Dividend Yield
- THCH N/A
- ZURA N/A
- EPS Growth
- THCH N/A
- ZURA N/A
- EPS
- THCH N/A
- ZURA N/A
- Revenue
- THCH $187,316,342.00
- ZURA N/A
- Revenue This Year
- THCH N/A
- ZURA N/A
- Revenue Next Year
- THCH N/A
- ZURA N/A
- P/E Ratio
- THCH N/A
- ZURA N/A
- Revenue Growth
- THCH N/A
- ZURA N/A
- 52 Week Low
- THCH $1.95
- ZURA $0.97
- 52 Week High
- THCH $5.15
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- THCH 39.96
- ZURA 70.35
- Support Level
- THCH $2.48
- ZURA $1.97
- Resistance Level
- THCH $2.60
- ZURA $2.10
- Average True Range (ATR)
- THCH 0.13
- ZURA 0.14
- MACD
- THCH 0.01
- ZURA 0.01
- Stochastic Oscillator
- THCH 33.70
- ZURA 90.76
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.